8-KMaterial AgreementsFinancial EventsExhibits & Filings

AbbVie Inc. 8-K Report, Material Agreement (Sep 6, 2018)

Filed September 6, 2018For Securities:ABBV

Summary

This 8-K filing by AbbVie Inc. (ABBV) on September 6, 2018, announces the execution of a new $3.0 billion unsecured revolving credit facility, effective August 31, 2018. This facility replaces a previous $3.0 billion revolving credit agreement that was terminated concurrently. The new credit facility has a five-year term, providing AbbVie with significant financial flexibility and access to capital for general corporate purposes. The company also amended its 364-day term loan credit agreement to align with the terms of the new revolving credit facility. The refinancing and new facility arrangements demonstrate AbbVie's proactive approach to managing its liquidity and debt structure, ensuring continued operational and strategic funding capacity. Investors should note the terms of the new facility, including its interest rate structure and covenants, which are standard for such unsecured financings.

Key Highlights

  • 1AbbVie entered into a new $3.0 billion unsecured revolving credit facility on August 31, 2018.
  • 2The new credit facility has a term of five years from the effective date.
  • 3The new facility replaces a previous $3.0 billion unsecured revolving credit agreement, which was terminated.
  • 4Borrowings under the new facility can bear interest at either a base rate or Eurocurrency rate, plus applicable margins.
  • 5Applicable margins are tiered based on AbbVie's public debt ratings, ranging from 0.000% to 1.325%.
  • 6The company also amended its 364-day term loan credit agreement to conform to the terms of the new credit facility.
  • 7The agreements contain standard affirmative and negative covenants, including a financial covenant.

Frequently Asked Questions

The primary purpose of this filing is to announce AbbVie's entry into a new $3.0 billion unsecured revolving credit facility and the termination of its previous revolving credit agreement. It also details an amendment to its 364-day term loan credit agreement.

The new facility is for $3.0 billion, is unsecured, and has a term of five years from August 31, 2018. It allows for borrowings based on either a base rate or a Eurocurrency rate, with applicable margins that vary based on AbbVie's credit ratings.

While the filing doesn't explicitly state the reason, replacing an existing facility with a new one often aims to secure more favorable terms, extend maturity dates, or align financing structures with current corporate strategies and market conditions. The new facility has a five-year term, potentially offering longer-term financial flexibility compared to the prior agreement which would have matured in October 2019.

This filing indicates AbbVie is proactively managing its liquidity. A revolving credit facility provides general corporate flexibility for working capital, potential investments, or other strategic initiatives. The filing itself does not specify any immediate plans for debt issuance or acquisitions, but it ensures capital is available should such opportunities arise.